Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 9c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of ($0.03), $0.09 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $7.29 million versus the consensus estimate of $7.55 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT